Radiopharm Theranostics RADX
NASDAQ RADX
$1.44 -0.18 (-11.11%)
As of: Oct 1, 2026 · 10:36 AM EDT

Radiopharm Theranostics (RADX) Total Current Liabilities (2024 - 2026)

Updated

Radiopharm Theranostics' Total Current Liabilities was $134,046 in fiscal Q4 2026 (quarter ended Jun 30, 2026), up 40.2% from $95,636 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Total Current Liabilities (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Total Current Liabilities at Radiopharm Theranostics came in at $128,341, down 99.1% from FY2025.

  • In earlier fiscal years, Total Current Liabilities was $14.93 million in FY2025 (-15.0%) and $17.58 million in FY2024.
  • The fiscal Q4 2026 figure marks the highest quarterly Total Current Liabilities since fiscal Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 54.90 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 41.64 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 27.73 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 31.75 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -31.55 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 25.50 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 11.02 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 32.65 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 3.94 Bn
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86 134,046.26
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 134,046.26
Jun 30, 2025 95,635.79
Dec 31, 2024 13.15 Mn
Jun 30, 2024 115,828.63
API Access

Radiopharm Theranostics Total Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-current-liabilities&ticker=RADX&period=max&api_key=YOUR_API_KEY